scholarly journals Real-life data – a characteristic of RA in patients with cardiovascular diseases on the background of treatment with biological agents

2019 ◽  
pp. 10-17
Keyword(s):  
Cardiovascular Diseases ◽  
Real Life ◽  
Biological Agents ◽  
Mean Values ◽  
Average Value ◽  
Life Data ◽  
Real Life Data ◽  
Significant Difference ◽  
Time Average ◽  
Therapeutic Behavior

The purpose of this study is to analyze real-life data in order to characterize patients with RA and cardiovascular diseases that are treated with biological agents. Material and Methods: In a retrospective study, data from real clinical practice were analyzed in 195 patients with seropositive RA, which are being treated with biological agents. Results: In patients with existing CVD, significantly higher mean ESR values ​​(23.95 vs. 19.31, p = 0.031) and CRP (6.41 vs. 3.36, p = 0.004) were detected over the period of the study period of treatment. In contrast to the laboratory parameters, mean values of clinical parameters of RA - TJC, SJC and VAS clinical sings did not show a significant difference in patients with and without CVD. The time average value of DAS28 (ESR) during the study period was significantly higher in patients with CVD (3.7 vs. 3.39, p = 0.002) compared to those without CVD. DAS28 (CRP) shows the same trend. In patients with CVD, the time average value of the follow-up indicator was 3.21, and in patients without CVD, 2.88 (p <0.001). Conclusion: The results of this study, in PA patients conducting treatment with biological agents in the real life, outside of the clinical study conditions, demonstrate that independently of treatment, patients with CVD continue to maintain higher background inflammation. An optimization of therapeutic behavior in real life is necessary to improve the long-term prognosis of these patients.

One-year real life data of our patients with moderate-severe Crohn’s disease who underwent ustekinumab therapy

2021 ◽  
pp. 003693302110085
Author(s):  
Ferhat Bacaksız ◽  
Derya Arı ◽  
Volkan Gökbulut ◽  
Ömer Öztürk ◽  
Ertuğrul Kayaçetin
Keyword(s):  
Clinical Remission ◽  
Disease Duration ◽  
Real Life ◽  
Biological Agents ◽  
Induction Treatment ◽  
Life Data ◽  
Early Access ◽  
Real Life Data ◽  
One Year ◽  
Access Program

Aim The aim of this study was to present one-year real-life data of our patients with CD who showed unresponsiveness and/or intolerance to biological agents and then received ustekinumab treatment through an early access program. Materials and methods The retrospective study reviewed the 52-week clinical data of 10 patients with moderate or severe CD who underwent ustekinumab therapy. Results The 10 patients comprised 7 (70%) men and 3 (30%) women with a mean age of 38 ± 11.3 years. Mean disease duration was 13.5 ± 8.5 years. Mean pretreatment CDAI score was 273.5 ± 92 and mean pretreatment HBI score was 11.6 ± 3.8. At the end of the 8-week intravenous induction treatment, 5 (55%) patients showed clinical remission according to the CDAI and HBI scores. Additionally, 62.5% of the patients were in clinical remission at the end of week 52 according to the CDAI and HBI scores. No drug-related side effects were observed in any patient throughout the treatment. Conclusion Ustekinumab appears to be effective and safe in the treatment of moderate and severe CD, particularly in cases of unresponsiveness and intolerance to biological agents such as anti-TNF, and in the achievement of clinical remission.

Neuropsychology in the Real World

2014 ◽  
Vol 25 (4) ◽  
pp. 233-238 ◽  
Author(s):  
Martin Peper ◽  
Simone N. Loeffler
Keyword(s):  
Neuropsychological Assessment ◽  
Real World ◽  
Ecological Validity ◽  
Real Life ◽  
Emotional States ◽  
Context Sensitive ◽  
Traditional Assessment ◽  
Life Data ◽  
Real Life Data ◽  
Assessment And Treatment

Current ambulatory technologies are highly relevant for neuropsychological assessment and treatment as they provide a gateway to real life data. Ambulatory assessment of cognitive complaints, skills and emotional states in natural contexts provides information that has a greater ecological validity than traditional assessment approaches. This issue presents an overview of current technological and methodological innovations, opportunities, problems and limitations of these methods designed for the context-sensitive measurement of cognitive, emotional and behavioral function. The usefulness of selected ambulatory approaches is demonstrated and their relevance for an ecologically valid neuropsychology is highlighted.

The epidemiology of thyroid cancer within a center of excellence in Athens: Real life data

2017 ◽  
Author(s):  
Eleni Pantazi ◽  
Alexios Travlos ◽  
Evaggelia Vogiatzi ◽  
Ifigenia Kostoglou-Athanassiou
Keyword(s):  
Thyroid Cancer ◽  
Real Life ◽  
Life Data ◽  
Center Of Excellence ◽  
Real Life Data
Sign in / Sign up

Export Citation Format

Share Document